Levodopa combined with carbidopa is the most effective medication for treating Parkinson’s disease motor symptoms. It has held that position for decades, and no newer drug has surpassed it. But “best” depends on your age, how far the disease has progressed, and which symptoms bother you most. Treatment typically starts with one medication and evolves into a combination strategy as the disease advances.
Why Levodopa Is Still the Gold Standard
Levodopa works by converting into dopamine in the brain, directly replacing the chemical that Parkinson’s disease depletes. Carbidopa is always paired with it to prevent levodopa from breaking down before it reaches the brain, which reduces nausea and other side effects. This combination (sold under brand names like Sinemet and Rytary) remains the single most effective treatment for the core motor symptoms: tremor, stiffness, and slowness of movement.
Clinical guidelines give levodopa/carbidopa the strongest recommendation as first-line therapy for adults over 65 and anyone with significant motor problems at diagnosis. For most people, it produces a clear, noticeable improvement in movement and daily function that other drug classes simply can’t match.
What Changes Based on Your Age and Stage
Not everyone starts on levodopa right away. The reason: long-term use is associated with a higher risk of involuntary movements called dyskinesias and “wearing-off” periods where the medication stops working before the next dose is due. These complications tend to emerge within the first five years of treatment, and they’re more common in people diagnosed at a younger age.
For younger patients or those with only mild symptoms, doctors often start with a different class of drug called MAO-B inhibitors. These medications (including rasagiline and selegiline) work by slowing the breakdown of whatever dopamine your brain still produces. They offer a modest but meaningful improvement in symptoms and can delay the point at which you need levodopa. The landmark DATATOP trial showed that selegiline delayed the need for stronger dopamine-boosting therapy in newly diagnosed patients.
Dopamine agonists are another option for initial treatment. They mimic dopamine’s action in the brain and are more effective at controlling motor symptoms than MAO-B inhibitors, but they carry a higher risk of side effects like daytime sleepiness, hallucinations, and impulse control problems (such as compulsive gambling or shopping). After starting on either an MAO-B inhibitor or a dopamine agonist, the other can be added before introducing levodopa, building a layered approach that helps minimize long-term complications.
Once motor symptoms progress enough to affect quality of life, levodopa becomes the cornerstone of treatment regardless of age.
Managing the “Wearing-Off” Problem
After several years on levodopa, many people notice that each dose doesn’t last as long as it used to. Symptoms creep back before it’s time for the next pill. These “off” periods can be unpredictable and frustrating. Several strategies help.
Your doctor may adjust the timing or size of your levodopa doses, switch to a longer-acting formulation, or add medications from other classes. MAO-B inhibitors, dopamine agonists, and COMT inhibitors (which block another enzyme that breaks down levodopa) can all extend the effective window of each dose. Guidelines recommend adding one agent from each class in a stepwise approach rather than piling them on all at once. A newer extended-release levodopa/carbidopa pill called Crexont was approved in August 2024 specifically to provide more consistent drug levels throughout the day.
For sudden off periods that strike without warning, an inhaled form of levodopa (Inbrija) acts as a rescue medication. You inhale the contents of two capsules through a small device when symptoms return, and it kicks in faster than waiting for your next oral dose. It can be used up to five times a day, with a maximum of 84 mg per episode.
Treating Dyskinesia
The involuntary, flowing movements that some people develop after years of levodopa therapy are called dyskinesias. They’re essentially the flip side of too much dopamine stimulation. Amantadine is the primary medication used to treat them. It has a unique combination of effects on both dopamine and glutamate signaling in the brain, and randomized controlled trials over the past several years have confirmed that it reduces dyskinesias while also helping smooth out motor fluctuations. Clinical guidelines recommend it specifically for this purpose in advanced Parkinson’s disease.
Medications for Non-Motor Symptoms
Parkinson’s disease affects far more than movement. Hallucinations, sleep disruption, and mood changes are common, and they often need their own treatment.
Hallucinations and Psychosis
Pimavanserin is the only antipsychotic designed specifically for Parkinson’s-related psychosis. Unlike older antipsychotics, it doesn’t block dopamine receptors, so it treats hallucinations and delusions without worsening motor symptoms. For people with Parkinson’s-related dementia and severe behavioral disturbances, low-dose clozapine is sometimes used, though it requires regular blood monitoring.
REM Sleep Behavior Disorder
Many people with Parkinson’s act out vivid dreams during sleep, sometimes injuring themselves or a bed partner. Clonazepam, a long-acting benzodiazepine, is widely considered the first-line treatment for this. Melatonin also has supporting evidence and is often tried first because it’s better tolerated. Ramelteon, a prescription sleep aid that targets melatonin receptors, has shown effectiveness at an 8 mg dose for sleep problems in Parkinson’s, particularly this type of dream-enacting behavior.
Advanced Delivery Options
When oral medications can no longer provide stable symptom control, newer delivery systems aim to keep drug levels steady throughout the day rather than cycling through peaks and valleys with each pill. Several options are now available or under review: subcutaneous pumps that deliver a continuous infusion of levodopa/carbidopa under the skin (similar to an insulin pump), and pump-patch devices that attach directly to the body. Continuous apomorphine infusion, another pump-based option, delivers a potent dopamine agonist under the skin for people with severe motor fluctuations. Deep brain stimulation and focused ultrasound are non-medication alternatives for advanced disease that doesn’t respond adequately to drugs.
Getting the Most From Levodopa
How you take levodopa matters almost as much as the dose. Protein in food competes with levodopa for absorption in the gut and transport into the brain, which means a high-protein meal can blunt the medication’s effect. The standard advice is to take levodopa 30 minutes before eating or one to two hours after a meal.
If you notice that protein-rich meals make your medication less effective, two approaches can help. You can save most of your protein intake for the evening, when a temporary dip in medication effectiveness is less disruptive. Or you can spread protein evenly across all meals so absorption stays more consistent throughout the day. Skipping protein entirely isn’t an option, since it’s essential for maintaining muscle and overall health.